Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models

Sleep disorders affect a substantial portion of the population, and finding effective treatments that work through natural biological pathways is a priority in neuroscience. This study by Mu, Qu, Yin, and colleagues investigated DSIP fusion peptides and their ability to cross the blood-brain barrier to treat insomnia.

The researchers used a Pichia pastoris expression system to produce DSIP fusion peptides and tested their blood-brain barrier permeability and therapeutic efficacy in a mouse model of insomnia induced by PCPA, a serotonin synthesis inhibitor. This innovative approach combined biotechnology with neuropharmacology.

The results demonstrated that the DSIP fusion peptides successfully crossed the blood-brain barrier and effectively alleviated insomnia symptoms in the animal model. This confirmed both the delivery feasibility and therapeutic efficacy of the engineered peptide.

For individuals struggling with insomnia and sleep disorders, this research advances DSIP as a peptide-based therapeutic option that works through the brain's natural sleep-regulating mechanisms. Unlike many conventional sleep medications, peptide-based approaches like DSIP may offer sleep support without the dependency risks associated with traditional sedatives.